Immune checkpoint inhibitors (ICIs), exemplified by Programmed Cell Death-1 (PD-1)/Programmed Death-ligand 1 (PD-L1) inhibitors, have conferred significant clinical benefits across various cancer types (1–7). Here, PDCD1 is linked to cancer.